Skip to content

Revitalization of Damaged Skin Due to Chronic Skin Diseases

Revitalization of Damaged Sking Due to Chronic Skin Diseases

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03485560
Enrollment
200
Registered
2018-04-02
Start date
2018-05-01
Completion date
2019-01-01
Last updated
2018-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis, Chronic Eczema, Psoriasis

Keywords

chronic skin disease, psoriasis, Eczema, atopic dermatitis

Brief summary

Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture of natural peptides and herbs. the main aim is to restore the normal skin appearance for the patient and control the episodes of flare.

Detailed description

Psoriasis is a chronic, immune mediated (type 2 and type 17) chronic skin disease. The production of the immune proteins that leads to continuous inflammatory mediated process. The result of chronic inflammation is they hyper keratotic layer of skin which gets attacks of atopic dermatitis leading to symptoms of itching, pruritis and in situ bleeding. ACE CSD, with the multiple factors that mediates the immune response and control the protein receptors, in addition to the multiple regeneration peptides that are specifically extracted from healthy skin of newly born sheep; in addition to multiple Chinese herbs that contains different anabolic factors was tested to be able to regenerate the damaged skin and locally modulate the immunity reactions so the skin can regenerate fully to replace the damaged skin with normal healthy skin.

Interventions

COMBINATION_PRODUCTACE CSD

Topical application of the ACE CSD 4 times daily.

Sponsors

Ace Cells Lab Limited
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Chronic skin condition lasts for more than 1 year. * tried traditional treatment with limited or without effect. * not on steroids for at least 6 weeks.

Exclusion criteria

* patients on steroid. * patients intolerable to protein or allergic to proteins * during pregnancy or lactation

Design outcomes

Primary

MeasureTime frameDescription
Regeneration of the damaged skin lesion6 - 9 monthsComplete regeneration of the affected skin lesions from the skin disease.

Secondary

MeasureTime frameDescription
Flare control1-3 monthsDuring the attacks of flare, the regenerated skin does not get affected nor show erythematous reaction

Countries

Serbia, United Kingdom

Contacts

Primary ContactDr. Alaa Abdelkarim MF Mohammed
dralaakarim@gmail.com+447473922553
Backup ContactDr. Diana Diana, MsC Dermatology
dr.dianadiana@outlook.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026